V VERTERO Trademark
V VERTERO is a USPTO trademark filed by Axial Therapeutics, Inc.. Status: Pending.
Trademark Facts
| Mark | V VERTERO |
|---|---|
| Serial Number | 99447651 |
| Status | Pending |
| Filing Date | 2025-10-16 |
| Mark Type | Combined |
| Nice Classes | 001 (Chemicals), 005 (Pharmaceuticals), 042 (Software & IT), 044 (Medical Services) |
| Owner | Axial Therapeutics, Inc. |
| Attorney of Record | Ian W. Gillies |
| Prosecution Events | 14 |
| Latest Event | NOAM on 2026-02-17 |
Goods & Services
Class 001: Chemicals, biochemicals, cells, and microbes for use in the manufacture of probiotic, microbe-targeted, or host-targeted pharmaceutical preparations, for in vitro and in vivo scientific or research use, and for use in industry and science; Chemical, biochemical and microbial products, namely, one or more of small molecules, proteins, antibodies, nucleic acids, probiotic bacteria, probiotic bacterial cultures, and microbes for the manufacture of probiotic, microbe-targeted, or host-targeted pharmaceutical preparations for the treatment, prevention, and detection of nervous system diseases and disorders, cancer, tumors, fibrosis, inflammation, microbe-related and microbiome-related conditions, and gastrointestinal and immunological diseases; Class 005: Probiotic, microbe-targeted, or host-targeted pharmaceutical preparations and substances for the treatment, prevention, and detection of nervous system diseases and disorders, cancer, tumors, fibrosis, inflammation, microbe-related and microbiome-related conditions, gastrointestinal and immunological diseases; Chemical, biochemical and microbial products, namely, one or more of small molecules, proteins, antibodies, nucleic acids, probiotic bacteria, probiotic bacterial cultures, and microbes being pharmaceutical preparations and substances for the treatment, prevention, and detection of central nervous system diseases and disorders, cancer, tumors, fibrosis, inflammation, microbe-related and microbiome-related conditions, and gastrointestinal and immunological diseases; Class 042: Providing medical research and scientific research information in the fields of pharmaceuticals, biochemistry, biotechnology, and clinical trials; drug discovery services; pharmaceutical research; research and development of new probiotic, microbe-targeted, or host-targeted phamaceutical products; research in the fields of biochemistry, biotechnology, and conducting clinical trials for others; Class 044: Providing medical information in the fields of diagnostic, prophylactic, and therapeutic properties of probiotic, microbe-targeted, or host-targeted pharmaceuticals